Drug Discovery World

JUNE 11, 2024

The European Medicines Agency has approved a Type II variation to the Summary of Product Characteristics (SmPC) for Kite’s chimeric antigen receptor (CAR)-T cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel).

Therapies 130

Therapies Clinical Trials Hospitals International 130

Drug Discovery World

AUGUST 22, 2022

Three international life sciences start-ups have received investment from the BioInnovation Institute (BII). . Our goal is to harness the untapped potential of European research, and at the BII we are passionate about helping each venture overcome potential hurdles and position them to attract top-quality international investment.

International 130

International Science Hospitals Drug Development 130

Drug Discovery World

MARCH 11, 2024

Following a separate submission process the World Health Organization has proposed the International Nonproprietary Name (INN) of cambritaxestat. Cambritaxestat is being developed as a first-in-class therapy for highly fibrotic cancer indications.

Therapies 173

Therapies Drugs FDA International 173

Drug Discovery World

MARCH 12, 2024

Elicera Therapeutics has entered a Material Transfer Agreement (MTA) with a prominent US cancer centre to evaluate the enhancing effect of the iTANK-technology in a novel T-cell receptor therapy targeting skin cancer and lung cancer.

Therapies 130

Therapies Immune Response Licensing Licensing 130

Drug Discovery World

MAY 18, 2023

Further projects will automate additional components of ScaleReady’s workflow, such as the robotic movement of G-Rex into and out of incubators. The post Collaboration to simplify cell therapy manufacturing appeared first on Drug Discovery World (DDW).

Therapies 130

Therapies Clinical Trials International Trials 130

Drug Discovery World

JUNE 19, 2024

DDW Editor Reece Armstrong speaks to Jasminka Taleska , Director, RLT HCS Readiness and Policy at Novartis, about the opportunities radioligand therapies (RLTs) represent in treating cancer patients. The post How ready are we for radioligand therapies? RA: What are the potentials of RLTs across cancer? JT: This is very important 6.

Therapies 147

Therapies Treatment Regulations Production 147

Drug Discovery World

JUNE 12, 2023

It is the UK’s first specifically designed accessible laboratory for the cell and gene therapy industry. This investment in Scotland builds upon CGT Catapult’s existing work supporting emerging advanced therapy clusters in the UK, with its Manufacturing Innovation Centres in Stevenage, Hertfordshire and Braintree, Essex.

Laboratories 130

Laboratories Therapies Clinical Trials International 130

Drug Discovery World

JUNE 13, 2023

revolution. Designed to automate the manufacturing of advanced therapies without significant process redevelopment, Constellation combines aseptic fluid handling technologies with advanced automation from the industry 4.0 revolution. Cellular Origins’ platform, Constellation has been designed to address this urgent need.

Therapies 130

Therapies Production International Marketing 130

Drug Discovery World

MARCH 16, 2023

The cell and gene therapy (CGT) market is rapidly expanding, and projections suggest it will reach over $90B by 2023. Challenges of cell and gene therapy manufacturing Compared to traditional biologics, CGTs are living drugs, making their development and manufacturing substantially more complex.

Therapies 130

Therapies FDA Approval Science Production 130

Science Daily: Pharmacology News

JUNE 5, 2024

A new clinical trial of five children with inherited deafness found administering gene therapy in both ears led to restored hearing and speech, and additional gains including sound source localization, ability to hear in noisy environments, and for two children, abillity to appreciate music.

Therapies 121

Therapies Trials Clinical Trials International 121

Drug Discovery World

NOVEMBER 14, 2023

Takeda’s Adzynma has become the first recombinant protein product approved in the US for prophylactic or on-demand enzyme replacement therapy (ERT) for congenital thrombotic thrombocytopenic purpura (cTTP). The post First therapy for very rare blood clotting disorder gets US greenlight appeared first on Drug Discovery World (DDW).

Therapies 130

Therapies FDA Approval Protein Production FDA 130

Drug Discovery World

AUGUST 29, 2023

A stem cell derived investigational therapy for treating Parkinson’s disease has shown promise in early clinical trials. The data were presented at the International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

Therapies 130

Therapies Clinical Trials Trials Disease 130

Drug Discovery World

DECEMBER 4, 2023

The investigational compound Elenagen is an experimental DNA therapy that consists of a circular piece of DNA called a plasmid that includes a gene for a human protein called p62/SQSTM1. The post DNA therapy effective against chemo-resistant ovarian cancer appeared first on Drug Discovery World (DDW).

DNA 147

DNA Therapies Packaging Vaccine 147

Drug Target Review

AUGUST 28, 2024

Once a patient develops advanced cirrhosis/end-stage liver disease there are no specific therapies to significantly avoid major decompensations and death in the next few years. Could you describe the platform of macrophage biology and cell engineering used by Resolution Therapeutics in developing their cell therapies?

Therapies 114

Therapies Disease Engineering Medical Schools 114

Drug Discovery World

FEBRUARY 23, 2024

Efficacy was evaluated in the Phase III trial FLAURA2 in 557 patients with EGFR exon 19 deletion or exon 21 L858R mutation-positive la/mNSCLC and no prior systemic therapy for advanced disease. The post Combination therapy reduced risk of lung cancer progression by 38% appeared first on Drug Discovery World (DDW).

Therapies 130

Therapies FDA Trials Treatment 130

Drug Discovery World

MARCH 2, 2023

The Avacta Therapeutics Science Day brought together senior company scientists and international oncology experts to provide an overview of the current development of the company’s cancer drug pipeline and the latest innovations in targeted oncology.

Therapies 130

Therapies Treatment Trials Disease 130

Drug Discovery World

SEPTEMBER 16, 2022

A biologic therapy for very young children with moderate to severe eczema (or atopic dermatitis) has been shown to be safe and effective in an international trial. The therapy is already licensed in the UK for adults and children aged six to 18, and was approved by the FDA in June 2022 for use in younger children.

Therapies 130

Therapies Licensing Licensing Clinical Research 130

Drug Discovery World

MAY 16, 2023

What are the global innovations in cell and gene therapy? What opportunities and challenges are emerging and can therapies get to market faster? Curbishley explains that as the wave of new therapies in development continues to increase, global pressures on manufacturing availability will become more acute.

Therapies 130

Therapies Clinical Trials Marketing Production 130

Drug Discovery World

OCTOBER 3, 2024

The new clinical trial data was shared at the 2024 International Congress of Parkinson’s Disease and Movement Disorders (MDS). ND0612 is an investigational drug-device combination therapy – a 24-hours/day, continuous subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD) for the treatment of motor fluctuations in people with PD.

Disease 147

Disease Clinical Trials Trials Therapies 147

Drug Discovery World

APRIL 17, 2024

Recombinant adeno-associated viruses (rAAVs) are considered a promising delivery system for gene therapy medicines. This webinar will detail how Oxford Nanopore evaluated long-read nanopore sequencing as a comprehensive and sensitive QC method for rAAVs which is supporting internal research activities at AstraZeneca.

DNA 246

DNA Packaging Virus International 246

Drug Discovery World

JANUARY 10, 2024

Speaking on the recent FDA statement, Bruce Levine, ISCT Immediate Past President and Lead Author on the publication, stated: “The fundamental question from this report is whether or not there is a causal link between CAR-T therapy and these rare T cell malignancy cases and in how many patients.

FDA 147

FDA Therapies International Treatment 147

DrugBank

JUNE 13, 2024

Unlike traditional oral medications with limited bioavailability and potential for erratic absorption, IDDS function as internal drug repositories, delivering precise doses of medication directly at the site of action or into the systemic circulation via precisely adjusted release mechanisms. 

Therapies 74

Therapies Drugs DNA Treatment 74

Drug Discovery World

JULY 14, 2023

awarded to progress ovarian cancer cell therapy NK:IO has been awarded £1.6m ($2.1m) in grant funding from Innovate UK’s New Cancer Therapeutics programme. £1m awarded to progress ovarian cancer cell therapy NK:IO has been awarded £1.6m ($2.1m) in grant funding from Innovate UK’s New Cancer Therapeutics programme. £1m

International 130

International Pharmaceutical Companies DNA Drugs 130

Drug Discovery World

FEBRUARY 13, 2024

The UK’s Education Secretary Gillian Keegan attended a meeting with the Cell and Gene Therapy Catapult (CGT Catapult) to discuss the role of apprenticeships in the advanced therapies industry. The ATAC programme, which was set up in 2018, is designed to train individuals to work in the advanced therapies industry.

Therapies 130

Therapies International Science Government 130

Drug Discovery World

JULY 5, 2024

Long-term, 25% of treated patients treated with evenamide as an add-on therapy met the criteria for remission, a result that Stephen Marder, Distinguished Professor of Psychiatry at the Semel Institute of Neuroscience & Human Behavior, has described as “remarkable and unprecedented”.

Pharmaceuticals 264

Pharmaceuticals Clinical Development International Therapies 264

Drug Discovery World

DECEMBER 1, 2023

The top stories: Potential disease-modifying therapy for Parkinson’s disease An experimental drug has shown potential as a disease-modifying therapy for Parkinson’s disease, according to a new study published in Nature Communications.

Therapies 130

Therapies Drugs Disease International 130

Drug Discovery World

APRIL 16, 2024

Recombinant adeno-associated viruses (rAAVs) are considered a promising delivery system for gene therapy medicines. This webinar will highlight how long-read nanopore sequencing as a comprehensive and sensitive QC method for rAAVs were evaluated — which is supporting internal research activities at AstraZeneca.

Packaging 130

Packaging DNA Virus International 130

Drug Discovery World

FEBRUARY 2, 2024

Sunday 4 February is World Cancer Day, an international awareness day led by the Union for International Cancer Control (UICC), so the round-up this week will focus on oncology, including the UK approval of a rare blood cancer drug and a novel production process for CAR-T therapies.

Pharmacokinetics 130

Pharmacokinetics Drugs International Clinical Trials 130

Drug Discovery World

JANUARY 18, 2024

Market opportunity estimated at over US$1 billion Largely due to the CRS risk (which can be life threatening), administration of cancer immunotherapies, such as bispecific antibodies, is currently restricted to specialist cancer centres which limits uptake of these therapies.

Treatment 162

Treatment Clinical Trials Immune Response Therapies 162

Drug Discovery World

SEPTEMBER 27, 2024

The main efficacy outcome measure was progression-free survival (PFS) as assessed by an independent review committee based on International Myeloma Working Group criteria. The therapy is also currently approved in more than 50 countries across two indications for the treatment of people with relapsed or refractory disease.

FDA Approval 130

FDA Approval FDA International Treatment 130

Drug Discovery World

AUGUST 2, 2023

into induction therapy and additionally, within post-consolidation therapy, demonstrated outstanding patient outcomes with overall survival (OS) of 86.0% The current standard of care includes multiple cycles of chemotherapy, surgery, radiotherapy, stem cell transplantation and anti-GD2 mAb treatment. s submission.

Licensing 246

Licensing Licensing Hospitals Therapies 246

Drug Discovery World

AUGUST 13, 2024

“We look forward to collaborating with Absci in leveraging the company’s generative AI platform in our ongoing efforts to advance cancer research and develop new therapies for our patients.”

Pharma Companies 162

Pharma Companies International Research Therapies 162

Drug Discovery World

MAY 1, 2024

Recombinant adeno-associated viruses (rAAVs) are considered a promising delivery system for gene therapy medicines. This webinar will detail how Oxford Nanopore evaluated long-read nanopore sequencing as a comprehensive and sensitive QC method for rAAVs which is supporting internal research activities at AstraZeneca.

Packaging 130

Packaging DNA Virus International 130

Drug Discovery Today

NOVEMBER 10, 2022

A team of surgeons and scientists from the UK, Sweden and Canada, funded by Rinri Therapeutics, has confirmed secure surgical access to the central core of the human cochlea The research, published in Scientific Reports, is critical to the first in-human trials of new cell, gene and drug therapies for the inner ear, and will assist with treatment for (..)

International 100

International Research Therapies Trials 100

Drug Discovery World

APRIL 24, 2024

Recombinant adeno-associated viruses (rAAVs) are considered a promising delivery system for gene therapy medicines. This webinar will detail how Oxford Nanopore evaluated long-read nanopore sequencing as a comprehensive and sensitive QC method for rAAVs which is supporting internal research activities at AstraZeneca.

DNA 130

DNA Packaging Virus International 130

Drug Discovery World

JULY 10, 2024

Upon success, Aptamer will progress to internally generating demonstrator data in animal models for evaluation by AstraZeneca. Reaching proof of principle in animal models will derisk the Optimer delivery platform and bring us closer to delivering targeted and effective gene therapies for patients.”

RNA 162

RNA International Therapies Marketing 162

Science Daily: Pharmacology News

NOVEMBER 27, 2023

An international team has shown that the injection of a type of stem cell into the brains of patients living with progressive multiple sclerosis (MS) is safe, well tolerated and has a long-lasting effect that appears to protect the brain from further damage.

Therapies 93

Therapies Trials International 93